Welcome to our dedicated page for cbdMD news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on cbdMD stock.
cbdMD, Inc. (NYSE American: YCBD) is a premier provider of high-quality, hemp-derived cannabidiol (CBD) products. Founded in 2015 and headquartered in Charlotte, North Carolina, cbdMD has quickly become one of the most highly trusted and recognized names in the CBD industry. The company offers a broad range of CBD products under its flagship brand cbdMD, as well as its pet-focused brand Paw CBD and its newly launched ATRx Labs line of functional mushroom supplements.
The company's product portfolio includes CBD tinctures, gummies, topicals, capsules, bath bombs, bath salts, sleep aids, and veterinarian-formulated pet CBD products like tinctures, chews, and topicals. It has built a robust distribution network, leveraging its own e-commerce platform, third-party online marketplaces, wholesalers, and a variety of brick-and-mortar retailers across the United States.
In recent developments, cbdMD has introduced innovative products such as the THCV+CBG Energy Softgels, which combine the potency of two dynamic cannabinoids with caffeine and B12 to enhance energy, focus, and clarity. The company's dedication to innovation is also evident in the launch of its CBD+CBG Oil Tincture and the introduction of a new Vice President of Wholesale Sales to expand its market reach.
Financially, cbdMD has been proactive in securing funding to support its growth. Recently, the company entered a securities purchase agreement, raising $1.25 million in gross proceeds to bolster working capital and support the national rollout of its ATRx Labs functional mushroom products. Despite reporting operational losses, cbdMD has implemented cost-cutting measures and strategic initiatives aimed at achieving profitability and enhancing shareholder value.
cbdMD's latest product,
cbdMD, Inc. (NYSE American: YCBD) reported financial results for Q3 2024 ending June 30, 2024. Key highlights include:
- Net sales of $5.1 million, down 15% YoY but up 18% sequentially
- Gross profit improved to 65% from 63% in Q3 2023
- Operating loss reduced to $0.38 million from $1.8 million in Q3 2023
- Net income of $0.46 million compared to a net loss of $1.7 million in Q3 2023
- Cash on hand increased to $2.3 million from $1.8 million at fiscal year-end 2023
The company achieved significant operational efficiencies, with SG&A expenses down and the best non-GAAP adjusted EBITDA result in its history. However, cbdMD received a non-compliance notice from NYSE American and must submit a plan to regain compliance by December 5, 2025.
cbdMD, Inc. (NYSE American: YCBD), a leading CBD company, has announced a conference call scheduled for August 14, 2024, at 4:20 p.m. Eastern Time. The call will discuss the company's third quarter fiscal 2024 financial results and business progress for the period ending June 30, 2024. Investors and interested parties can join the call using the following details:
- USA/Canada: 844-763-8274
- International: 647-484-8814
- Replay available: USA/Canada (877-344-7529), International (412-317-0088), Passcode: 5067217
A webcast replay will be accessible until August 14, 2025, via the provided link.
cbdMD (NYSE: YCBD) announced the publication of its human clinical trial data in the Journal of the International Society of Sports Nutrition. The study, conducted by the University of South Carolina, evaluated the effects of daily intake of 100 mg of cbdMD's Broad Spectrum CBD blend over 12 weeks on healthy adults.
Key findings include significant pain reduction, improved psychological well-being in male participants, and reduced perceived stress in female participants. The study confirmed the safety and tolerability of the product, aligning with previous research on safe CBD consumption levels.
cbdMD highlighted the trial as evidence of their commitment to science, safety, and efficacy, reinforcing their leadership in the CBD industry.
cbdMD (NYSE American: YCBD) has received a noncompliance notice from NYSE American, indicating that the company does not meet the continued listing standards. As of March 31, 2024, the company reported stockholders' equity of $3.1 million, below the required $4 million. Additionally, it has reported losses in three of the last four fiscal years. cbdMD must submit a compliance plan by July 5, 2024, to regain compliance by December 5, 2025. Although the notice does not affect the company's immediate operations or trading status, the stocks will carry a "BC" designation for being below compliance. cbdMD aims to achieve profitability and has announced cost reductions to be implemented by August 2024. The company is also considering converting Preferred Stock liabilities to equity to meet compliance but is not assured of success.
cbdMD (NYSE American: YCBD) has launched the ATRx Labs Premium Mushroom Line exclusively at GNC stores nationwide. The line consists of four products targeting various health needs: Energy & Stamina, Memory & Cognition, Digestion & Microbiome, and Immune Support. Each supplement merges powerful mushroom extracts with clinically studied ingredients to support natural wellness. This strategic partnership with GNC aims to meet the increasing consumer demand for natural health solutions, marking cbdMD's expansion in the wellness sector beyond CBD products.
On May 16, 2024, cbdMD announced its new Max Chill Dragon Fruit D9 Gummies, featuring a 1:1 CBD to THC ratio. Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, aiming to provide balanced relaxation and stress relief. The gummies are vegan, gluten-free, and have a tropical dragon fruit flavor. Priced at $39.99, they are available on cbdMD's website.
cbdMD reported its financial results for Q2 of fiscal 2024, showing a slight increase in operational losses from $1.4 million to $1.5 million YoY. Net sales decreased by 30% to $4.4 million, with DTC sales dropping 26% and wholesale sales falling 44%. Despite these setbacks, the company launched its ATRx Platinum line in GNC stores, aiming to expand market presence. Cost-cutting measures are projected to save $2.4 million annually, potentially leading to positive cash flow by August. The company also closed $1.25 million in net financing through convertible notes. Net loss for the quarter was $4 million, or $1.35 per share, attributable to a non-cash contingency liability.
cbdMD, Inc. will host a conference call on May 15, 2024, to discuss their second-quarter fiscal 2024 financial results and business progress. The company is a prominent CBD company with a strong reputation. The call will take place at 4:20 p.m. Eastern Time.
FAQ
What is the current stock price of cbdMD (YCBD)?
What is the market cap of cbdMD (YCBD)?
What does cbdMD, Inc. specialize in?
What are cbdMD's latest product innovations?
How does cbdMD distribute its products?
What recent financial steps has cbdMD taken?
What is the significance of cbdMD's ATRx Labs line?
Is cbdMD financially stable?
What challenges is cbdMD currently facing?
Where is cbdMD headquartered?
Who recently joined the cbdMD team?
What are cbdMD's future plans?
